Parallel Advisors’s Rhythm Pharmaceuticals RYTM Stock Holding History

Parallel Advisors’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2K	Hold	21	–	–	﹤0.01%	3648
2026 Q2	$2.33K	Sell	21 -4	-16%	-$362	﹤0.01%	3486
2026 Q1	$2.17K	Hold	25	–	–	﹤0.01%	3343
2025 Q4	$2.68K	Hold	25	–	–	﹤0.01%	3056
2025 Q3	$2.52K	Buy	25 +6	+32%	+$557	﹤0.01%	2992
2025 Q2	$1.2K	Hold	19	–	–	﹤0.01%	3164
2025 Q1	$1.01K	Hold	19	–	–	﹤0.01%	3127
2024 Q4	$1.06K	Hold	19	–	–	﹤0.01%	3101
2024 Q3	$995	Buy	19 +14	+280%	+$671	﹤0.01%	3037
2024 Q2	$205	Hold	5	–	–	﹤0.01%	3200
2024 Q1	$217	Hold	5	–	–	﹤0.01%	3140
2023 Q4	$230	Buy	+5	New	+$158	﹤0.01%	3153
2022 Q1	–	Sell	-50	Closed	–	–	3239
2021 Q4	$0	Sell	50 -131	-72%	-$1.47K	﹤0.01%	3268
2021 Q3	$2K	Buy	+181	New	+$2.76K	﹤0.01%	2720
2020 Q4	–	Sell	-90	Closed	-$2K	–	2696
2020 Q3	$2K	Hold	90	–	–	﹤0.01%	2337
2020 Q2	$2K	Buy	+90	New	+$1.75K	﹤0.01%	2231

Other funds holding RYTM

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Capricorn Fund Managers London, United Kingdom $1.06B AUM 45.98% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

iA Global Asset Management Quebec, Quebec, Canada $8.54B AUM 39.73% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return

Parallel Advisors's RYTM Position: Q3 2026 in Review

Parallel Advisors held its Rhythm Pharmaceuticals (RYTM) position steady in Q3 2026 at 21 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #3648.

Parallel Advisors first reported a position in RYTM in Q2 2020 and has held it in 16 quarters since. The position peaked at $2.68K in Q4 2025. 83 funds tracked by Wall St. Rank hold RYTM as of Q3 2026.

Parallel Advisors held 21 shares of Rhythm Pharmaceuticals worth $2K as of Q3 2026.
Parallel Advisors left its Rhythm Pharmaceuticals share count unchanged in Q3 2026.
Rhythm Pharmaceuticals made up ﹤0.01% of Parallel Advisors's portfolio in Q3 2026, its #3648 holding.
Parallel Advisors first reported a position in Rhythm Pharmaceuticals in Q2 2020 and has held it in 16 quarters since.
Parallel Advisors's Rhythm Pharmaceuticals position peaked at $2.68K in Q4 2025.
83 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q3 2026.

Based on Parallel Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.